Does Response of RAS Blockade on Serum K+ Levels Influence Its Glycemic-Mitigating Response When Combined With Hydrochlorothiazide?
Article first published online: 26 APR 2012
© 2012 Wiley Periodicals, Inc.
The Journal of Clinical Hypertension
Volume 14, Issue 7, pages 415–421, July 2012
How to Cite
Deedwania, P. C., Zappe, D. H., Egan, B. M., Purkayastha, D., Samuel, R. and Sowers, J. R. (2012), Does Response of RAS Blockade on Serum K+ Levels Influence Its Glycemic-Mitigating Response When Combined With Hydrochlorothiazide?. The Journal of Clinical Hypertension, 14: 415–421. doi: 10.1111/j.1751-7176.2012.00635.x
- Issue published online: 2 JUL 2012
- Article first published online: 26 APR 2012
- Manuscript received: November 3, 2011; Revised: February 22, 2012; Accepted: March 1, 2012
- 1ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997.
- 2Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906., , , et al.
- 17Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. J Clin Hypertens (Greenwich). 2008;10:894–903., , , et al.